ORNIDYL
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORNIDYL is an injectable small-molecule drug approved in 1990 by Sanofi. The specific indication and mechanism of action are not publicly detailed in available data, limiting clinical positioning assessment.
LOE Approaching
Product approaching loss of exclusivity signals potential team contraction and shift toward generic/lifecycle management rather than growth-focused roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ORNIDYL offers limited growth opportunity; the product has no linked job openings and is approaching loss of exclusivity. This role is best suited for professionals with managed decline or generic transition expertise seeking stability over expansion.
Brand ManagerProduct Manager
Worked on ORNIDYL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.